INNOVIVA, INC. Increase (Decrease) in Deferred Leasing Fees
INNOVIVA, INC. (INVA) reported Increase (Decrease) in Deferred Leasing Fees of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLeasingFees · last filed 2023-02-28
- INNOVIVA, INC. increase (decrease) in deferred leasing fees for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in deferred leasing fees for the quarter ending 2021-09-30 was $0.00.
- INNOVIVA, INC. increase (decrease) in deferred leasing fees for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in deferred leasing fees for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in deferred leasing fees for fiscal 2022 was $0.00.
- INNOVIVA, INC. increase (decrease) in deferred leasing fees for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- INNOVIVA, INC. increase (decrease) in deferred leasing fees for fiscal 2020 was $135.00K, a 58.46% decline from fiscal 2019.
- INNOVIVA, INC. increase (decrease) in deferred leasing fees for fiscal 2019 was $325.00K, a 0.00% change from fiscal 2018.
| Period end | Increase (Decrease) in Deferred Leasing Fees 3 month | Increase (Decrease) in Deferred Leasing Fees 6 month | Increase (Decrease) in Deferred Leasing Fees 9 month | Increase (Decrease) in Deferred Leasing Fees 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $0.00 derived: sum of 2 quarters · filed 2021-10-27 | $0.00 10-Q · filed 2021-10-27 | $270.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $0.00 10-Q · filed 2021-07-29 | $270.00K derived: sum of 3 quarters · filed 2023-02-28 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-28 | $270.00K derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $54.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $54.00K derived: sum of 3 quarters · filed 2023-02-28 | $135.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | -$216.00K derived: sum of 2 quarters · filed 2021-10-27 | -$135.00K 10-Q · filed 2021-10-27 | -$53.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $135.00K 10-Q · filed 2021-07-29 | $217.00K derived: sum of 3 quarters · filed 2022-03-17 | $298.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $81.00K 10-Q · filed 2021-04-28 | $163.00K derived: sum of 2 quarters · filed 2022-03-17 | $244.00K derived: sum of 3 quarters · filed 2022-03-17 | $325.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $82.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $163.00K derived: sum of 2 quarters · filed 2022-03-17 | $244.00K derived: sum of 3 quarters · filed 2022-03-17 | $325.00K 10-K/A · filed 2022-03-17 |
| 2019-09-30 | $81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $162.00K derived: sum of 2 quarters · filed 2020-10-28 | $243.00K 10-Q · filed 2020-10-28 | $325.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $162.00K 10-Q · filed 2020-07-29 | $244.00K derived: sum of 3 quarters · filed 2021-02-25 | $325.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $81.00K 10-Q · filed 2020-04-29 | $163.00K derived: sum of 2 quarters · filed 2021-02-25 | $244.00K derived: sum of 3 quarters · filed 2021-02-25 | $325.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $163.00K derived: sum of 2 quarters · filed 2021-02-25 | $244.00K derived: sum of 3 quarters · filed 2021-02-25 | $325.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $162.00K derived: sum of 2 quarters · filed 2019-10-30 | $243.00K 10-Q · filed 2019-10-30 | $325.00K derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $162.00K 10-Q · filed 2019-07-24 | $244.00K derived: sum of 3 quarters · filed 2020-02-19 | |
| 2018-03-31 | $81.00K 10-Q · filed 2019-05-01 | $163.00K derived: sum of 2 quarters · filed 2020-02-19 | ||
| 2017-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $325.00K 10-K · filed 2020-02-19 | ||
| 2017-09-30 | $243.00K 10-Q · filed 2018-10-31 | |||
| 2016-12-31 | $190.00K 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |